Skip to content

PHARMAQ: what changed

BE 0479.480.106NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€22,968
2024 · €48,398-€25,430
Equity
€128,237
2024 · €105,269+€22,968
Cash
€178,789
2024 · €131,170+€47,619
Balance sheet total
€375,271
2024 · €325,323+€49,949

Largest movements

2024 to 2025
Assets
  • Cash +€47,619

    up €47,619 (+36.3%), from €131,170 to €178,789

    mainly Trade debts (+€35,464) and Net result for the year (+€22,968)

  • Deferred charges and accrued income +€9,606

    up €9,606 (+20.5%), from €46,947 to €56,553

  • Stocks and contracts -€7,628

    down €7,628 (-5.4%), from €140,434 to €132,806

Equity and liabilities
  • Trade debts +€35,464

    up €35,464 (+62.3%), from €56,923 to €92,387

  • Profit (loss) carried forward +€22,968

    up €22,968 (+75.8%), from -€30,289 to -€7,321

  • Other debts -€7,058

    down €7,058 (-4.5%), from €157,362 to €150,304

Income statement
  • Write-downs +€14,036

    first reported in 2025, at €14,036

  • Staff costs +€5,983

    up €5,983 (+15.8%), from €37,977 to €43,960

  • Gross operating margin -€5,620

    down €5,620 (-6.5%), from €87,077 to €81,457

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2024 €48,398
Gross operating margin -€5,620
Staff costs -€5,983
Write-downs -€14,036
Financial income +€28
Financial charges +€181
Result 2025 €22,968
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€47,619
Investment €0
Financing €0
Cash 2024 €131,170
Net result for the year +€22,968
Stocks and contracts +€7,628
Receivables within one year -€352
Deferred charges and accrued income -€9,606
Trade debts +€35,464
Tax, wage and social debts -€1,426
Other debts -€7,058
Cash 2025 €178,789
brings cash intakes cash out
Every line side by side 46 lines
Line Code 2024 2025 Change %
Total assets 20/58 €325,323 €375,271 +€49,949 +15.4%
Formation expenses 20 €0 €0 =
Fixed assets 21/28 €1,000 €1,000 = 0.0%
Intangible fixed assets 21 €0 €0 =
Tangible fixed assets 22/27 €0 €0 =
Plant, machinery and equipment 23 €0 €0 =
Furniture and vehicles 24 €0 €0 =
Financial fixed assets 28 €1,000 €1,000 = 0.0%
Current assets 29/58 €324,323 €374,271 +€49,949 +15.4%
Stocks and contracts in progress 3 €140,434 €132,806 -€7,628 -5.4%
Stocks 30/36 €140,434 €132,806 -€7,628 -5.4%
Amounts receivable within one year 40/41 €5,770 €6,123 +€352 +6.1%
Trade receivables 40 €3,481 €1,374 -€2,107 -60.5%
Other amounts receivable 41 €2,290 €4,749 +€2,459 +107%
Cash at bank and in hand 54/58 €131,170 €178,789 +€47,619 +36.3%
Deferred charges and accrued income 490/1 €46,947 €56,553 +€9,606 +20.5%
Total equity and liabilities 10/49 €325,323 €375,271 +€49,949 +15.4%
Equity 10/15 €105,269 €128,237 +€22,968 +21.8%
Contributions 10/11 €62,000 €62,000 = 0.0%
Contributions outside capital 11 €62,000 €62,000 = 0.0%
Other 1109/19 €62,000 €62,000 = 0.0%
Reserves 13 €73,558 €73,558 = 0.0%
Non-distributable reserves 130/1 €6,200 €6,200 = 0.0%
Reserves not available under the articles 1311 €6,200 €6,200 = 0.0%
Distributable reserves 133 €67,358 €67,358 = 0.0%
Profit (loss) carried forward 14 -€30,289 -€7,321 +€22,968 +75.8%
Amounts payable 17/49 €220,053 €247,034 +€26,981 +12.3%
Amounts payable within one year 42/48 €220,053 €247,034 +€26,981 +12.3%
Trade debts 44 €56,923 €92,387 +€35,464 +62.3%
Suppliers 440/4 €56,923 €92,387 +€35,464 +62.3%
Taxes, remuneration and social security 45 €5,769 €4,343 -€1,426 -24.7%
Taxes 450/3 €0 €185 +€185
Remuneration and social security 454/9 €5,769 €4,159 -€1,611 -27.9%
Other amounts payable 47/48 €157,362 €150,304 -€7,058 -4.5%
Remuneration, social security and pensions 62 €37,977 €43,960 +€5,983 +15.8%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) 631/4 - €14,036 +€14,036
Other operating charges 640/8 €187 €187 = 0.0%
Gross operating margin 9900 €87,077 €81,457 -€5,620 -6.5%
Operating profit (loss) 9901 €48,913 €23,274 -€25,639 -52.4%
Financial income 75/76B €60 €88 +€28 +46.2%
Recurring financial income 75 €60 €88 +€28 +46.2%
Financial charges 65/66B €575 €394 -€181 -31.5%
Recurring financial charges 65 €575 €394 -€181 -31.5%
Profit (loss) for the period before taxes 9903 €48,398 €22,968 -€25,430 -52.5%
Profit (loss) for the period 9904 €48,398 €22,968 -€25,430 -52.5%
Profit (loss) for the period to be appropriated 9905 €48,398 €22,968 -€25,430 -52.5%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€191,354 to €242,249

Midpoint €212,560 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

Adjusted equity €128,237
Capitalised earnings €254,471 to €356,260
Indication €191,354 to €242,249

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€128,237
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€128,237

Capitalised earnings

net result for the year (9904)
2025
€22,968
2024
€48,398
2023
€35,510
2022
€54,912
excluding non-recurring income and charges
€56,991
2021
-€3,641
excluding non-recurring income and charges
-€3,491
Average result
€35,626
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€254,471 / €296,883 / €356,260

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 18 November 2026 via checked.be.